A

ADC Therapeutics SA
D

ADCT

1.45000
USD
-0.25
(-14.71%)
مغلق
حجم التداول
78,532
الربح لكل سهم
-1
العائد الربحي
-
P/E
-3
حجم السوق
185,118,158
نظرة عامة
أصول ذات صلة
AKAM
AKAM
D
Akamai Technologies
91.720
-8.210(-8.22%)
97.990+6.270(+6.84%)
CRWD
CRWD
D
CrowdStrike Holdings
249.370
-11.860(-4.54%)
253.680+4.310(+1.73%)
CSCO
CSCO
D
سيسكو
113.650
-1.430(-1.24%)
114.920+1.270(+1.12%)
FFIV
FFIV
D
F5
457.17
-19.13(-4.02%)
475.50+18.33(+4.01%)
FTNT
FTNT
D
Fortinet
184.140
-6.590(-3.46%)
186.320+2.180(+1.18%)
NTAP
NTAP
D
NetApp
222.190
-16.760(-7.01%)
229.010+6.820(+3.07%)
PANW
PANW
D
Palo Alto Networks
375.21
-21.81(-5.49%)
379.00+3.79(+1.01%)
ZS
ZS
D
Zscaler
220.730
-7.960(-3.48%)
222.650+1.920(+0.87%)
المزيد

العنوان: ADC Therapeutics SA

القطاع: الرعاية الصحية
الصناعة: Drug Manufacturers - Specialty & Generic
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more linesof systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).